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Abstract: Ectodomain shedding is a key mechanism of several biological processes, including cell-
communication. Disintegrin and metalloproteinases (ADAMs), together with the membrane-type
matrix metalloproteinases, play a pivotal role in shedding transmembrane proteins. Aberrant
shedding is associated to several pathological conditions, including arthritis. Tissue inhibitor of
metalloproteases 3 (TIMP-3), an endogenous inhibitor of ADAMs and matrix metalloproteases
(MMPs), has been proven to be beneficial in such diseases. Thus, strategies to increase TIMP-3
bioavailability in the tissue have been sought for development of therapeutics. Nevertheless, high
levels of TIMP-3 may lead to mechanism-based side-effects, as its overall effects on cell behavior
are still unknown. In this study, we used a high-resolution mass-spectrometry-based workflow to
analyze alterations induced by sustained expression of TIMP-3 in the cell surfaceome. In agreement
with its multifunctional properties, TIMP-3 induced changes on the protein composition of the
cell surface. We found that TIMP-3 had differential effects on metalloproteinase substrates, with
several that accumulated in TIMP-3-overexpressing cells. In addition, our study identified potentially
novel ADAM substrates, including ADAM15, whose levels at the cell surface are regulated by the
inhibitor. In conclusion, our study reveals that high levels of TIMP-3 induce modifications in the cell
surfaceome and identifies molecular pathways that can be deregulated via TIMP-3-based therapies.
Keywords: tissue inhibitor of metalloproteases 3 (TIMP-3); metalloproteinases; ectodomain shed-
ding; proteomics
1. Introduction
The proteolytic cleavage of transmembrane proteins and the consequent release of
their ectodomains in the extracellular milieu, known as ectodomain shedding, is a key
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mechanism in several biological processes, including cell communication, adhesion, and
transport [1]. About 2% of transmembrane proteins undergo ectodomain shedding, with
the disintegrin and metalloproteinases (ADAMs) and the membrane-type members of the
matrix metalloprotease family (MT-MMPs) playing a major role in this process [2,3]. The
activity of ADAMs and MT-MMPs, as well as subsequent ectodomain shedding, have to be
finely regulated. This occurs at several levels, including inhibition by the tissue inhibitors
of metalloproteases (TIMPs) [4]. Differently from the other three mammalian TIMPs,
which have a very restricted inhibitory profile against ADAMs, TIMP-3 can inhibit several
members of this family, including ADAM10, 12, 17, 28, and 33 [4]. In addition, TIMP-3
is able to inhibit the matrix metalloproteinases (MMPs), including the membrane-type
MMPs that represent another major class of proteinases involved in ectodomain shedding.
Uniquely among TIMPs, TIMP-3 is also able to inhibit members of the related family of
disintegrin and metalloproteinases with thrombospondin motifs (ADAMTSs) [4].
Aberrant cell-surface proteolysis has detrimental effects on cell behavior and is asso-
ciated with the development of several pathological conditions, including inflammatory
diseases and cancer [1]. For its ability to modulate ectodomain shedding, in addition to con-
trol ECM turnover, TIMP-3 has been proven protective in a number of diseases. Ablation
of TIMP-3 in mouse, and subsequent loss of ADAM17 inhibition, leads to arthritis, chronic
hepatic inflammation, insulin resistance, and liver/heart failure due to excessive release
of tumor necrosis factor (TNF) [5–7]. Furthermore, aberrant ADAM10 activity in TIMP-3
deficient mice promoted liver failure in a model of hepatic ischemia/reperfusion injury [8].
TIMP-3 is often silenced in malignancies and its deficiency in mouse enhances tumor
progression [9]. Conversely, by targeting ADAM17, there is an overexpression of TIMP-3
dampened TNF-release that ameliorated the development of arthritis in a murine model
of the disease [10]. Similarly, TIMP-3 overexpression in mouse macrophages reduced adi-
pose inflammation, insulin resistance, nonalcoholic fatty liver disease, and atherosclerotic
plaques in an atherosclerosis mouse model [11,12]. Transgenic overexpression of TIMP-3,
as well as treatment with the purified protein, reduced cancer progression in vivo [13]. As
a consequence of its beneficial effects, strategies to increase TIMP-3 levels in the tissue
have been widely sought as a potential therapeutic treatment for diseases characterized by
enhanced proteolysis. Nevertheless, overall effects of increased TIMP-3 on cell behavior
are unknown, and it is difficult to predict whether TIMP-3-based therapies may lead to
mechanism-based side effects due to high levels of the inhibitor.
Unbiased proteomics allows one to perform a comprehensive analysis of molecular
pathways that can be affected by high levels of TIMP-3 and predict potential side effects
that may be induced by TIMP-3-based therapies. In this study, we generated a TIMP-3
stably transfected cell line, in which sustained expression of the inhibitor was maintained
by using hygromycin B as a selection reagent. As such, we developed a high-resolution
mass spectrometry-based workflow to evaluate changes induced by the overexpression of
TIMP-3 in the cell surface proteome. Our analysis revealed that TIMP-3 induced significant
changes in the cell surfaceome, which is in line with its ability to inhibit several members
of ADAMs and other classes of metalloproteinases. Several, but not all, known metal-
loproteinase substrates accumulated on the cell surface of TIMP-3 overexpressing cells.
In addition, we found a number of type-1 transmembrane proteins, including ADAM15,
whose levels were increased in response to TIMP-3, that can be novel ADAM substrates.
Furthermore, we discovered that hygromycin B as a selection reagent can be used for stably
transfected cells that have unexpected effects on cells, including altering stability of specific
proteins, as we demonstrated on the ephrin type-A receptor 4 (EphA4).
In conclusion, this study provides a comprehensive analysis of modifications occurring
in the cell surfaceome as a consequence of increased expression of TIMP-3, identifies
proteins that accumulate at the cell surface, including potentially novel ADAM substrates,
and molecular pathways that may be affected by increased levels of TIMP-3. Furthermore,
it can serve as a valuable tool to predict mechanism-based side effects that may arise
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from TIMP-3-based therapies and to analyze functions of proteases and inhibitors in a
comprehensive cell context-dependent manner.
2. Results
2.1. Surfaceome Analysis of TIMP-3 Overexpressing Cells
In order to identify alterations induced by TIMP-3 in the cell surface proteome, we
stably transfected HEK 293 cells to generate a TIMP-3 overexpressing cell line (TIMP-3/HEK)
and developed a high-resolution mass spectrometry-based workflow to perform an unbiased
quantitative analysis of cell surface protein levels in these cells. HEK 293 cells express high
levels of ADAMs and therefore they have high shedding potential. For this reason, HEK 293
cells are commonly utilized as a preliminary model to investigate shedding of transmembrane
proteins with strong implications in disease, including Alzheimer’s-related amyloid precursor
protein (APP) [14]. Cell membrane proteins of TIMP-3/HEK or control HEK 293 cells were
labelled using Sulfo-NHS-biotin and isolated through streptavidin pull-down.
These proteins were analyzed via LC-MS/MS and levels assessed through label-free
quantification. The analysis detected 3052 proteins, of which 325 cell membrane proteins
were comprised of both integral and peripheral membrane proteins, based on UniProt
annotation (Figure 1A, Supplementary Table S1). In addition to cell membrane proteins,
the mass-spectrometry analysis detected intracellular proteins. This is in line with pre-
vious reports, as the cytoskeletal network that forms strong physical links between the
plasma membrane and intracellular components is unspecific when binding to the strep-
tavidin resin. Further, biotin acts as a cofactor of carboxylases and, to a certain extent,
cell penetration of the reagent acts in spite of its negatively charged sulpho group [15,16].
Nevertheless, enrichment of cell membrane proteins reduces sample complexity and al-
lows mass-spectrometry detection of low abundant membrane proteins that would not be
detected in a whole cellular proteome analysis, as their signal would be covered by that of
high abundant intracellular proteins [15,17]. Proteins above the false discovery rate curves
(shown as dashed grey hyperbolic curves in Figure 1B and 1C; FDR p = 0.05; s0 = 0.1) were
considered as differentially abundant proteins. Moreover, 30.15% of the cell membrane
proteins were significantly regulated in TIMP-3/HEK cells, further indicating the multi-
functional properties of TIMP-3. Among them, 45 were less abundant in TIMP-3/HEK
and, conversely, 53 proteins were increased in TIMP-3/HEK, such as glypican (GPC1),
protein S100A8, and S100A9 that together formed the calprotectin complex (Figure 1B,
Supplementary Table S1). In addition, the analysis detected 102 transmembrane type-1
proteins, 38 type-2, 214 multi-pass transmembrane proteins, and 23 other proteins with dif-
ferent topologies (Figure 1A, Supplementary Table S1). ADAMs and MT-MMPs, of which
TIMP-3 is an endogenous inhibitor, mainly cleave type 1 transmembrane proteins, thereby
promoting release of their ectodomains [1]. For this reason, we focused our analysis on
the 102 transmembrane type-1 proteins. In total, 28 of these proteins significantly accumu-
lated on the cell surface of TIMP-3/HEK (Figure 1C, Table 1), which is in agreement with
reduced metalloproteinase-mediated shedding in the presence of high levels of TIMP-3. As
expected, several of these proteins were known to undergo metalloproteinase-dependent
shedding, including inactive tyrosine-protein kinase 7 (PTK7), podocalyxin-like protein 2
(PODXL2), and desmoglein 2 (DSG2) (Figure 1C, Table 1) [18,19]. Interestingly, not all
ADAM substrates increased upon TIMP-3 overexpression. Indeed, a number of adhesion
molecules (CADM1, MCAM, ALCAM, NCAM1, and CADM4), integrins (ITGA6, ITGA2,
ITGAV, ITGA5, and ITGA1), ephrin proteins, and receptors (EPHA7, EPHB2, EFNB1, and
EPHB4), as well as other proteins known to be ADAM substrates (SDC4, PROCR, etc.), did
not accumulate on the cell surface of TIMP-3/HEK cells (Supplementary Table S1). Other
than known ADAM substrates, 13 additional transmembrane type-1 proteins accumulated
on the cell surface of TIMP-3/HEK, which could potentially be novel substrates of ADAMs
or other metalloproteinases: DSC1, PVR, DSG1, PCDH7, ADAM15, TPBG, BTN2A1, KIR-
REL, PLXNA1, PVRL2, NCSTN, EGFR, and PTGFRN (Table 1). In total, 153 proteins were
not statistically evaluated, as they were not identified in at least 2 biological replicates of
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TIMP-3/HEK and control cells (Supplementary Table S1). Among these, the cell membrane
proteome analysis identified a number of ADAM substrates in the control HEK 293 cells
that, rather than accumulating, were not present in TIMP-3/HEK. This group had two
ADAM10 substrates, EphA4 and LRP-1 (Supplementary Table S1) [20,21].
1 
Figure 1. Analysis of cell membrane composition of TIMP-3 overexpressing cells. (A) Number and
topology of membrane proteins detected in the surfaceome of TIMP-3/HEK cells. (B) Volcano plot
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showing the -log10 of p-values versus the log2 of protein ratio between TIMP-3 overexpressing HEK
293 cells (TIMP-3-HEK) and control HEK 293 cells (HEK ctrls) of 325 membrane proteins (n = 3).
Proteins significantly regulated are displayed as the filled dots above the false discovery curves (grey
dashed hyperbolic curves; computed by Perseus software with FDR p = 0.05; s0 = 0.1). Red dots
correspond to less abundant proteins, blue dots to more abundant proteins in TIMP-3/HEK cells.
(C) Volcano plot showing the 102 type-1 proteins detected in the cell membrane of TIMP-3/HEK cells.
In conclusion, our mass spectrometry-based analysis identified major changes induced
by TIMP-3 in the cell surfaceome. As expected from increased metalloproteinase inhibition,
several metalloproteinase substrates accumulated on the cell surface, as well as other
proteins that could be novel ADAM substrates. Interestingly, another group of known
ADAM substrates, including a number of adhesion molecules, integrins, and ephrin
proteins, did not increase on the cell surface of TIMP-3/HEK.
Table 1. Type 1 transmembrane proteins significantly increased at the cell surface of TIMP-3 overexpressing cells.
Protein Name Protein ID Gene Name p-Value Ratio MP Substrate
Desmocollin-1 Q08554 DSC1 1.86 × 10−4 8.40 unknown
Poliovirus receptor P15151 PVR 8.86 × 10−3 5.56 unknown
Roundabout homolog 1 Q9Y6N7 ROBO1 3.11 × 10−2 5.13 [22]
Desmoglein-1 Q02413 DSG1 7.70 × 10−4 4.69 unknown
Protocadherin-7 O60245 PCDH7 1.13 × 10−3 4.29 unknown
Ephrin type-A receptor 2 P29317 EPHA2 1.87 × 10−3 4.01 [23]
Podocalyxin-like protein 2 Q9NZ53 PODXL2 3.19 × 10−3 3.87 [18]
Natural cytotoxicity triggering receptor 3 ligand 1 Q68D85 NCR3LG1 2.40 × 10−2 3.46 [24]
Receptor tyrosine-protein kinase erbB-2 P04626 ERBB2 5.72 × 10−3 2.98 [25]
Disintegrin and metalloproteinase
domain-containing protein 15 Q13444 ADAM15 3.32 × 10
−2 2.92 unknown
Trophoblast glycoprotein Q13641 TPBG 2.18 × 10−3 2.87 unknown
Butyrophilin subfamily 2 member A1 Q7KYR7 BTN2A1 3.75 × 10−2 2.80 unknown
Inactive tyrosine-protein kinase 7 Q13308 PTK7 4.54 × 10−3 2.73 [26]
Plexin-B2 O15031 PLXNB2 1.78 × 10−4 2.73 [18]
Kin of IRRE-like protein 1 Q96J84 KIRREL 8.80 × 10−4 2.69 unknown
Desmoglein-2 Q14126 DSG2 2.53 × 10−3 2.67 [19]
Plexin-A1 Q9UIW2 PLXNA1 1.82 × 10−4 2.65 unknown
Nectin-2 Q92692 PVRL2 1.91 × 10−2 2.56 unknown
Prostaglandin F2 receptor negative regulator Q9P2B2 PTGFRN 2.90 × 10−5 2.48 unknown
CD276 antigen Q5ZPR3 CD276 9.90 × 10−4 2.11 [27]
Epidermal growth factor receptor P00533 EGFR 1.43 × 10−2 2.03 unknown
Nicastrin Q92542 NCSTN 6.48 × 10−4 2.02 unknown
Chondroitin sulfate proteoglycan 4 Q6UVK1 CSPG4 5.52 × 10−2 1.94 [28]
Receptor-type tyrosine-protein phosphatase F P10586 PTPRF 2.45 × 10−2 1.91 [18]
Insulin-like growth factor 1 receptor P08069 IGF1R 1.92 × 10−2 1.76 [29]
Basigin P35613 BSG 1.79 × 10−2 1.76 [30]
Protocadherin-9 Q9HC56 PCDH9 4.60 × 10−2 1.66 [18]
Integrin beta-1 P05556 ITGB1 2.85 × 10−2 1.61 [31]
Protein name: proteins increased in TIMP-3/HEK above the FDR curve (FDR p = 0.05; s0 = 0.1) ID: UniProt accession number of the protein.
Ratio: mean ratio of label-free quantification intensities between TIMP-3/HEK and control HEK293 cells (n = 3). p-value: for three biological
replicates. MP substrate: proteins that undergo metalloproteinase-dependent shedding and their relative reference articles.
2.2. Validation of the Surfaceome Analysis
In order to validate results of the surfaceome analysis, we evaluated the changes
of a number of TIMP-3 regulated transmembrane proteins using Western blotting as an
orthogonal method. TIMP-3 is a secreted protein that inhibits metalloproteases when in the
extracellular milieu. Indeed, the large majority of metalloproteases were synthesized in an
inactive form comprising a pro-domain that prevents TIMP-3 binding before its removal.
This occurred either in the late stages of the secretory pathway or after secretion in the
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extracellular milieu [32,33]. In this study, we aimed to identify consequences of TIMP-3
overexpression; thus, we first confirmed that TIMP-3 accumulated in the conditioned
media of TIMP-3/HEK cells (Figure 2A; levels of TIMP-3 in the respective cell lysates
are shown in Supplementary Materials). As a consequence of TIMP-3 overexpression
and metalloprotease inhibition, levels of PTK7 decreased in the conditioned media and
increased in the cell lysate of TIMP-3/HEK compared to the controls, similarly to those
of APP, another well-characterized ADAM-substrate was used as a control (Figure 2) [14].
Proteomic analysis identified ADAM15 as a protein regulated by TIMP-3 and thus as a
potential ADAM substrate. Nevertheless, its levels were altered neither in the cell lysate
nor in the conditioned media of TIMP-3/HEK (Figure 2). For this reason, we isolated cell
membrane proteins through biotinylation and streptavidin pulldown similarly to how as
it was done within the proteomic workflow. In line with the proteomics results, levels of
ADAM15 at the cell surface increased in TIMP-3/HEK, as well as those of the ADAM sub-
strates PTK7 and APP (Figure 3). Treatment of HEK 293 cells with marimastat, a synthetic
metalloproteinase inhibitor, clearly reduced shedding of ADAM15, in a similar manner
as PTK7 and APP (Figure 4). This indicates that ADAM15 undergoes metalloprotease-
dependent shedding and that TIMP-3 can stabilize it at the cell surface by an additional
unknown mechanism.
Proteomics found that levels of the ADAM10 substrate CADM1 slightly decreased
at the cell surface of TIMP-3/HEK cells rather than accumulating, as was expected by
higher TIMP-3 expression and metalloprotease inhibition (Figure 1C, Supplementary
Table S1) [34]. Immunoblotting showed that both TIMP-3 and marimastat did not prevent
CADM1 shedding under these experimental conditions (Figures 2 and 4), and its decrease
on the cell membrane did not reach statistical significance (Figure 3). This confirmed the
proteomic results that the ADAM substrate CADM1 does not accumulate at the cell surface
upon TIMP-3 overexpression. In line with the surfaceome analysis, levels of SDC4, another
protein that undergoes metalloproteinase-dependent, and TIMP-3-sensitive shedding, was
not altered on the cell surface of TIMP-3/HEK (Supplementary Table S1, Figure 3), further
indicating that not all metalloproteinase substrates effectively accumulated at the cell
surface in response to increased levels of the inhibitor [35]. Finally, we analyzed via Western
blotting levels of EphA4, an ADAM10 substrate that the mass-spectrometry-based analysis
consistently quantified in HEK control cells, but it was below the limit of quantification
in TIMP-3/HEK cells (Supplementary Table S1). Western blotting with two different
antibodies, targeting the N-terminal or the C-terminal domain of EphA4, confirmed the
mass-spectrometry data in that levels of the protein in both lysates (Figure 2A,C) and cell
membranes (Figure 3) of TIMP-3 overexpressing cells markedly decreased compared to
HEK control cells.
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Figure 2. Analysis of protein changes by immunoblotting. (A) Immunoblots showing protein abundance of TIMP-3, PTK7, 
APP, ADAM15, and CADM1 in the conditioned media of TIMP-3/HEK and control HEK 293 cells, as well as levels of 
PTK7, APP, ADAM15, CADM1 and EphA4 in the cell lysates. Calnexin and GAPDH were used as loading controls. Den-
sitometric quantifications of specific proteins in the conditioned media (B) and cell lysates (C) are displayed as mean 
Figure 2. nalysis of protein changes by immunoblotting. (A) Immunoblots showing protein abundance of TIMP-3, PTK7,
APP, ADAM15, and CADM1 in the conditioned media of TIMP-3/HEK and control HEK 293 cells, as well as levels of PTK7,
APP, ADAM15, CADM1 and EphA4 in the cell lysates. Calnexin and GAPDH were used as loading controls. Densitometric
quantifications of specific proteins in the conditioned media (B) and cell lysates (C) are displayed as mean values ± standard
deviation (** p < 0.01, *** p < 0.005, Student’s t-test; from 3 to 6 separate experiments have been performed and analyzed).
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the endocytic receptor [36]. Given that another member of the ephrin-type A receptors, 
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ADAM15 in condition d m dia or lysates of HEK 293 cells treated with or without marimastat (control). GAPDH was used
as a loading control. Densito etric quantifications shown as mean values ± standard deviation; *** p < 0.005, Student’s
t-test; (n = 6).
2.3. Hygromycin B Promotes Decrease of EphA4 Levels
A nu ber of proteins were only identified in control HEKs, but not in the surfaceome
of TIMP-3 overex ess g cells (Suppl mentary Table S1). Among these proteins, LRP-1
and EphA4 are well chara terized ADAM10 substrates, and therefore we e xpected to
ccumulate on th cell surface as a consequence of incre sed TIMP-3 exp ssion [20,21].
LRP-1 decreased on the cell surface, which was validated via flow cytometry (Figure 5A),
may pot nti lly be provoked by sustained endocytosis of TIMP-3, one f the LRP-1 ligands
with highest affinity f r the receptor [36]. However, the molecular mechanism leading
to a decrease of EphA4 levels remains elusive. Thus, we further investigated the molec-
ular mechanism leading to this unpredicted phenotype of TIMP-3/HEK cells. EphA4
transcript levels were indistinguishable in TIMP-3/HEK or control cells, indicating that
EphA4 was post-translationally regulated in TIMP-3/HEKs (Figure 5B). We previously
found that TIMP-3 accelerated the endocytosis of LRP-1 ligands with a lower affinity for
the endocytic receptor [36]. Given that another member of the ephrin-type A receptors,
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EphA2, associates with LRP-1, we hypothesized that LRP-1 could regulate levels of EphA4,
with TIMP-3 being able to accelerate the process [37]. For this reason, we used RAP, an
extensively characterized LRP-1 inhibitor, to test whether EphA4 could be endocytosed by
LRP-1 through a process involving TIMP-3 [38]. RAP effectively blocked LRP-1-mediated
endocytosis, thereby slowing down TIMP-3 turnover and promoting its accumulation in
the conditioned media, both in TIMP-3/HEK and control cells (Figure 5C). Similarly, RAP
increased levels of EphA4, suggesting it as a novel LRP-1 ligand. Nevertheless, RAP failed
to rescue levels of EphA4 in TIMP-3/HEK, indicating that its endocytosis and subsequent
degradation are not dependent on TIMP-3 (Figure 5C). We previously characterized EphA4
as an ADAM10 substrate, whose shedding was clearly inhibited when cells were treated
with the ADAM10 inhibitor GI 254023X [21]. Similarly, addition of exogenous TIMP-3
to HEK 293 cells promoted accumulation of EphA4 compared to non-treated controls
(Figure 5D). This was in contrast with EphA4 decrease in TIMP-3 overexpressing cells. We
hypothesized that TIMP-3 could have an intracellular function, and to further address the
discrepancy between TIMP-3 overexpression and its exogenous addition, we tested the
effects on EphA4 of overexpression of TIMP-1, another TIMP that is also known to inhibit
ADAM10 [39]. Similarly to TIMP-3, TIMP-1 overexpression led to a reduction of EphA4
levels compared to controls (Figure 5E), indicating that this mechanism is not specifically
promoted by TIMP-3. TIMP-1 or TIMP-3 were inserted in the same vector carrying the
hygromycin B resistance gene, and TIMP overexpressing cells were maintained in me-
dia supplemented with the same amount of the selection reagent before being used for
experiments. Thus, we hypothesized that hygromycin B treatment could promote such
a reduction in EphA4 levels. In order to confirm this hypothesis, we cultured TIMP-3
overexpressing HEK 293 cells with increasing concentrations of hygromycin B, and then
levels of EphA4 were analyzed. No differences in viability between cells supplemented
with Hygromycin B and non-treated controls were detected (Supplemental Materials).
Maintaining TIMP-3/HEK cells in hygromycin B promoted decrease of EphA4 levels in
a dose-dependent manner, with the selection reagent having an effect at concentrations
as low as 200 µg/mL (Figure 5F). Furthermore, we transfected HEK 293 cells with an
empty vector, carrying the hygromycin B resistance gene, but lacking the TIMP-3 sequence.
When treated with hygromycin B, these cells displayed lower levels of EphA4 compared
to control cells (Figure 5G). These results clearly indicated that hygromycin B can have
unexpected effects on transgenic cells carrying the hygromycin B resistance gene.
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Figure 5. Treatment with hygromycin B of transgenic cells lowers levels of EphA4. (A) Levels of LRP-1 on TIMP-3/HEK or
control cells was measured by flow cytometry and plotted as the average of mean fluorescent intensities (MFI) ± standard
deviation (n = 3). (B) Expression levels of EphA4 mRNA in TIMP-3/HEK and control HEK 293 cells plotted as relative
2−∆∆CT (n = 4) (C) Immunoblots and their respective quantification (n = 4) showing levels of EphA4 in TIMP-3/HEK or
control HEK 293 cell lysates, in the absence or presence of 500 nM RAP. Actin was used as a loading control. (D) Immunoblots
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and their respective quantification (n = 9) showed levels of EphA4 in lysates of HEK 293 cells supplemented with TIMP-
3-containing or control conditioned media. GAPDH was used as a lading control. (E) Immunoblots and their respective
quantification (n = 3) showed levels of EphA4 TIMP-1 overexpressing (TIMP-1/HEK) or control HEK 293 cells. Calnexin
was used as a loading control. (F) Immunoblots and their respective quantification (n = 3) showed levels of TIMP-3 in the
conditioned media, and EphA4 in the lysate of TIMP-3/HEK or control HEK 293 cells treated with different concentrations
of hygromycin B (0–800 µg/mL). Actin was used as a loading control. (G) Immunoblots showed levels of EphA4 in the cell
lysate of HEK 293 cells, transfected with pCEP4 and treated with or without 400 µg/mL hygromycin B. Actin was used a
loading control. All densitometric quantifications shown as mean values ± standard deviation; (** p < 0.01, *** p < 0.005,
Student’s t-test).
3. Discussion
Ectodomain shedding is a regulatory mechanism in which the ectodomain of trans-
membrane proteins is proteolytically released from the cell surface into the extracellular
milieu. This mechanism plays a key role in a number of cellular processes, including
cell-cell communication, immunity, adhesion, and cellular transport [1]. Several cytokines
(TNF) and growth factors (EGF-like ligands, including TGFα, amphiregulin, and HB-EGF)
are synthesized as transmembrane precursors that need to be shed from the cell surface
in order to bind their specific receptor and trigger the signaling cascade [40]. In addition,
surface levels and the function of other transmembrane proteins, including signaling recep-
tors, endocytic receptors, and cell-adhesion molecules, can be regulated via ectodomain
shedding [1]. The family of ADAMs is a major class of membrane-tethered metallopro-
teinases involved in the ectodomain shedding of membrane components [2]. In addition to
ADAMs, MMPs play a significant role in this process. The membrane-type group of MMPs
(MT-MMPs) possess a transmembrane domain that localize them in proximity of their
ligands at the cell surface [3]. Other members of the MMP family, despite being secreted in
the extracellular space, can bind to cell membrane components, including proteoglycans,
and release transmembrane proteins [33].
Among the four mammalian TIMPs, TIMP-3 has the broader inhibitory profile, being
able to inhibit several members of the ADAM family (including ADAM10, 12, 17, 28, and
33), MT-MMPs (including MT1-, MT3 and MT5-MMP), and soluble MMPs/ADAMTSs [4].
For this reason, TIMP-3 has been proven to be protective in a number of diseases char-
acterized by enhanced proteolysis. Loss of TIMP-3 in mice leads to dysregulated TNF
release and aberrant MMP and ADAMTS activity, thereby promoting increased cartilage
breakdown in both models of inflammatory and surgically-induced arthritis, while ar-
ticular injection of TIMP-3 ameliorated the pathology in a rat meniscal tear model of
osteoarthritis [41,42]. TIMP-3 has been considered as a tumor suppressor in several human
cancer types, as it inhibits cancer cell migration and invasion [13]. Ablation of TIMP-3
in mouse enhanced inflammation by dysregulating the activity of ADAM17 (a TIMP-3
target metalloproteinase) and the subsequent release of its substrate TNF, thus promoting
insulin resistance and hepatosteatosis [5]. Conversely, by targeting the ADAM17/TNF
axis, overexpression of TIMP-3 in mouse macrophages reduced adipose inflammation,
insulin resistance, and nonalcoholic fatty liver disease, other than reducing atherosclerotic
plaques in a mouse model of atherosclerosis [11,12,43]. Loss of TIMP-3 in mouse promoted
aberrant shedding of E-cadherin by ADAM10, another TIMP-3 target metalloproteinase,
and consequent disruption the E-cadherin/beta-catenin complex from the cell surface,
thus provoking enhanced hepatocyte cell death and liver failure in a murine model of
hepatic ischemia/reperfusion injury [8]. On these premises, it is clear that TIMP-3 has been
considered as an excellent drug target in diseases characterized by enhanced proteolysis.
There has been considerable interest in understanding factors regulating levels of the
inhibitor in the tissue in order to develop therapeutics. Nevertheless, given that TIMP-3 is
a multifunctional protein with several target metalloproteinases and binding partners, its
therapeutic increase may lead to unwanted on-target side effects.
In order to predict molecular pathways that can be deregulated in response to high
levels of TIMP-3, we used high-resolution quantitative proteomics to analyze changes in
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the surfaceome of cells expressing high levels of the inhibitor. By using this method, we
found that several, but not all metalloproteinase substrates, effectively accumulated at
the cell surface of TIMP-3 overexpressing cells. Post-translational regulation of surface
levels of a specific protein can be complex, as it does not depend only on shedding but
also on its rate of secretion and endocytosis. In addition, ectodomain shedding itself can
be regulated by multiple members of the metalloproteinase family, or involving members
of other families of sheddases, such as BACE secretases and rhomboids [1,44]. Our study
suggests that accumulation of some metalloproteinase substrates—and therefore specific
molecular pathways—can be more responsive to TIMP-3 than others. Indeed, we found
that a number of metalloproteinase substrates did not increase at the cell surface of HEK
cells upon TIMP-3 overexpression. Among them, we characterized the ADAM substrate
CADM1 [34]. Levels of CADM1 were slightly decreased on TIMP-3/HEK when measured
by proteomics, although this decrease did not reach statistical significance when analyzed
by immunoblotting (this small discrepancy between immunoblotting and proteomics can
be due to the label-free quantification analysis, which is more accurate in recognizing little
protein changes as it allows for the reduction of the variability between different biological
replicates by normalizing their total protein amounts). Neither TIMP-3 nor a synthetic
inhibitor of metalloproteases (marimastat) affected CADM1 shedding, suggesting that
this process is not dependent on ADAMs, at least under these experimental conditions.
Shedding of specific ADAM substrates can be different in different cells and in response
to different stimuli. For example, acitretin stimulates ADAM10 to cleave APP in neurons,
but not NrCAM, another well-known ADAM10 substrate [45]. The differential shedding
of a specific ADAM substrate does not depend only on the protease activity but also
on two groups of seven membrane spanning proteins, the tetraspanins and the inactive
rhomboids, which have recently emerged as essential regulators of ADAM10 and ADAM17,
respectively [46,47]. These protein regulators can integrate different cues, activate their
cognate protease and address it towards specific groups of substrates [48]. Clearly, shedding
regulation is highly multifactorial; thus, the proteomic approach that we used in this study
can be a very powerful tool to investigate, in a comprehensive and cell context-dependent
manner, the effects of sheddases and their inhibitors on cell behavior.
In addition to known metalloproteinase substrates, we identified several other proteins
that accumulated at the cell surface of TIMP-3 overexpressing cells. Within this group, there
are potential novel metalloproteinase substrates and proteins that can be indirectly regu-
lated by the inhibitor. Levels of PTGFRN, for instance, decrease in the secretome of TIMP-3
expressing cells, further indicating that these proteins can be novel metalloproteinase sub-
strates, potentially ADAM10, as it resulted the most regulated proteinase by overexpression
of the inhibitor [21]. Despite stabilizing ADAM15 on the cell surface, TIMP-3 overexpres-
sion did not reduce levels of shed ADAM15 in the conditioned medium. Nevertheless, the
synthetic inhibitor of metalloproteases marimastat clearly inhibited its shedding, suggest-
ing that ADAM15 can indeed undergo a metalloproteinase-dependent release, but that
the mechanism by which TIMP-3 controls cell surface levels of ADAM15 may be different
from its inhibition. We found it intriguing that levels of ADAM15, a sheddase itself, can be
regulated by metalloproteinase-dependent shedding [49]. Although its substrate repertoire
is quite limited, with only few proteins shown to be cleaved in vitro, ADAM15 is associated
to development of age-related diseases, including osteoarthritis [50–53]. This indicates that
the substrate spectrum, and therefore functions of this metalloproteinase, can be broader
than what is currently known. It would be interesting to evaluate whether shedding of
ADAM15 alters its substrate repertoire, in a similar manner as it does for ADAM10 and
ADAM17, with the shed form of the enzyme being able to cleave different proteins from
its membrane-tethered counterpart, thus eliciting its protective effects in osteoarthritis
development [54].
Hygromycin B is an is an aminocyclitol antibiotic produced by Streptomyces hygroscopi-
cus and developed in the 1950s as an anthelminthic agent in swine. In the early 1980s, gene
sequence and enzymatic function of hygromycin B phosphotransferase (HPH) (the gene
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conferring resistance to the antibiotic) were characterized [55]. Since then, hygromycin B
and its resistance gene HPH have been extensively used in cell biology to select transfected
cells and ensure expression of transgenic genes. Hygromycin B is recommended for use as
a selection agent at 100–800 µg/mL and its side effects are associated to the sustained treat-
ment of transfected cells carrying the HPH transgene, which have not yet been reported
in the literature. HPH expression in transgenic mice (referred to as hygR mice) causes
resistance to toxic effects of hygromycin B in vivo and an 89-fold increase in the lethal dose
compared to wild-type controls [56]. Nevertheless, at high doses, hygromycin B induced
toxic effects in hygR transgenic mice, including acute inflammation, hepatocellular fatty
change and necrosis, and acute tubular nephrosis, culminating in liver and kidney failure.
In line with these results, our study displayed that sustained treatment with hygromycin B
of stable transfected cells can lead to unwanted side effects. We found that EphA4, a well
characterized ADAM10 substrate, unexpectedly was reduced in TIMP-3/HEK cells [21].
We demonstrated that such effects were not induced by TIMP-3, but by hygromycin B
treatment. Considering that the hygromycin B HPH system is one of the most used in
molecular biology to produce stable transfected cell lines, our results highlight the urge
of a more comprehensive analysis of hygromycin B side effects. A proteomic analysis of
transgenic cells expressing the HPH but no other transgene could be particularly suitable
to evaluate such effects.
In conclusion, TIMP-3 is beneficial in a number of diseases characterized by enhanced
proteolysis. Thus, we developed a high-resolution mass spectrometry-based workflow
to analyze alterations induced by TIMP-3 in the cell surfaceome and predict potential
mechanism-based side-effects that can arise from TIMP-3-based therapies. We found
that the inhibitor promoted major changes in the cell surfaceome, which is in line with
its broad inhibitory profile and its various biological activities. We identified a number
of proteins that accumulated at the cell surface in response to the increased expression
of TIMP-3, suggesting specific molecular pathways that would be more responsive to
high concentrations of the inhibitor and that could be potentially deregulated by TIMP-3-
based therapies.
4. Materials and Methods
4.1. Generation of TIMP-3 and TIMP-1 Overexpressing Cells
Recombinant human C-terminally FLAG-tagged TIMP-3 or TIMP-1 was inserted in
a pCEP4-based expression vector (Invitrogen, Loughborough, Leicestershire, UK) using
the PCR method, as previously described [57]. Human embryonic kidney HEK293 cells
were transfected with either TIMP-3 or TIMP-1 expression plasmid by lipofection with
FuGENE6 (Roche Applied Science, Basel, Switzerland) and transfected cells selected by
treatment with 800 µg/mL hygromycin B (Thermo Scientific, Waltham, MA, USA) over
3 weeks. Transfected cell lines were maintained under standard cell culture conditions
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% (v/v) fetal calf serum,
penicillin (100 units/mL), streptomycin (100 units/mL), and 800 µg/mL hygromycin B at
37 ◦C in 5% CO2, unless differently stated.
4.2. Cell Membrane Proteome Analysis of TIMP-3 Overexpressing Cells
TIMP-3/HEK were cultured in a complete medium supplemented with 800 µg/mL
hygromycin B to ensure stable maintenance of the plasmid encoding TIMP-3 and its ex-
pression at high levels. TIMP-3/HEK or HEK 293 cells were seeded in 6-well plates,
cultured until confluence in complete media without hygromycin B, and then incubated in
serum-free DMEM for 24 h. Then, cell membranes were labelled by using EZ-Link Sulfo-
NHS-LC-Biotin (Thermo Scientific, Waltham, MA, USA). After washing cells three times
with PBS and 100 mM glycine to quench and remove excess biotin reagent, membrane
proteins were isolated using a streptavidin pull-down (PierceTM High Capacity Strepta-
vidin Agarose, Thermo Fisher Scientific, Waltham, MA, USA). Proteins were loaded and
separated on a 10% Tris/glycine SDS gel. Afterwards, qualitatively equal gel slices were
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cut out from the gel. Proteins in the gel slices underwent tryptic digestion as previously
described [58]. Generated peptides were applied to LC-MS/MS analysis. To achieve high
sensitivity, a nano-LC-MS/MS setup was used that included a nano-LC system (EASY-
nLC 1000, Proxeon—part of Thermo Scientific, Waltham, MA, USA) with an in-house
packed C18 column (30 cm × 75 µm ID, ReproSil-Pur 120 C18-AQ, 1.9 µm, Dr. Maisch
GmbH, Ammerbuch-Entringen, Germany) coupled online via a nano-spray flex ion source
equipped with a PRSO-V1 column oven (Sonation, Biberach, Germany) to a Q-Exactive
mass spectrometer (Thermo Scientific, Waltham, MA, USA). Peptides were separated
with a reverse-phase chromatography using a 180 min binary gradient of water (A) and
acetonitrile (B) containing 0.1% formic acid at 50 ◦C column temperature.
4.3. Proteomic Data Analysis
The data were analyzed using Maxquant software (maxquant.org, Max-Planck In-
stitute Munich, version 1.5.2.6 [59]) and searched against a reviewed canonical FASTA
database of homo sapiens from UniProt (downloaded on December 12th 2014; comprising
16685 IDs), as previously described [21]. Trypsin was defined as protease and two missed
cleavages were allowed for the database search. The option first search was used to re-
calibrate the peptide masses within a window of 20 ppm. For the main search peptide
and peptide fragment mass tolerances were set to 4.5 and 20 ppm, respectively. Car-
bamidomethylation of cysteine was defined as a static modification. Protein acetylation
at the N-terminus and oxidation of methionine were set as variable modifications. Only
unique peptides were used for label-free quantification (LFQ). The Perseus software plat-
form (http://www.perseus-framework.org, (accessed on 15 October 2020) copyright of
Max Planck Institute of Biochemistry- Martinsried- Munich; Germany) was used to analyze
the statistical significance of changes in protein levels between TIMP-3/HEK and control
cells [60]. LFQ values were log2 transformed and a two-sided Student’s t-test was used for
statistical analysis. A false discovery rate to 0.05 and s0 to 0.1 were set as the threshold for
statistically significant alterations.
4.4. Methods to Validate Surfaceomics
TIMP-3/HEK cells were maintained in complete media supplemented with 800 µg/mL
hygromycin B. Then, TIMP-3/HEKs (or control HEK 293 cells) were seeded and grown in
6-well plates until confluence in complete media without hygromycin B. Finally, cells were
incubated in serum-free medium for 24 h before levels of specific proteins were analyzed
by Western blotting or FACS. Similarly, HEK 293 cells were grown to confluence and then
incubated in serum-free medium containing 10 µM marimastat or DMSO for 24 h, before
Western blotting analysis.
• Western blotting. Conditioned media were collected and proteins precipitated with
5% v/v trichloroacetic acid (Sigma, Aldrich, St. Louis, MO, USA) before being resus-
pended in Laemmli sample buffer (Bio-Rad, Hercules, CA, USA). Cells were collected
with STET lysis buffer (50 mM Tris, pH 7,5, 150 mM NaCl, 2 mM EDTA, 1% Triton),
containing protease inhibitor cocktail (1:500, P-2714, Sigma, Aldrich, St. Louis, MO,
USA). Alternatively, cell membranes were labelled by using EZ-Link Sulfo-NHS-
LC-Biotin and membrane proteins isolated, as described above (Section 4.2). Either
conditioned media, lysate or membrane proteins were loaded onto an acrylamide gel
and analyzed using SDS-PAGE electrophoresis, followed by immunoblotting. The
following antibodies were used: anti-TIMP-3 (AB6000, Sigma, Aldrich, St. Louis, MO,
USA), anti-EphA4 (targeting C-terminal EphA4, 6H7 Sigma, Aldrich, St. Louis, MO,
USA; targeting the N-terminal EphA4, 35/EphA4, BD Biosciences, Franklin Lakes,
NJ, USA), anti-calnexin (ADI-SPA-860-F, ENZO lifescience, Farmingdale, NY, USA),
anti-GAPDH (88845, Cell Signaling, Danvers, MA, USA), anti-PTK7 (AF4499, R&D
systems, Minneapolis, MN, USA), anti-APP (clone 22c11, Sigma, Aldrich, St. Louis,
MO, USA), CADM1 (TSLC1 H-300, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
ADAM15 (HPA011633, Atlas Antibodies, Bromma, Sweden), SDC4 (ab24511, Abcam,
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Cambridge, UK), and actin (81178, Santa Cruz, Santa Cruz, CA, USA). For each exper-
iment, 3 to 9 biological replicates were analyzed (number and raw quantifications are
shown in Supplemental Materials). Bands corresponding to each protein were quanti-
fied using Image Lab software (Bio-Rad, Hercules, CA, USA) and normalized to the
mean of the original non-normalized control values (HEK 293 cells for TIMP-3/HEK
or DMSO-treated HEK 293 cells for marimastat-treated cells). A two-sided Student’s
t-test was used to evaluate proteins statistically significantly regulated. A p-value less
than 0.05 was set as the significance threshold.
• Cells were collected with ice-cold staining buffer (PBS 1X, FBS 2%, 2 mM EDTA),
washed, and resuspended in 100 µL of staining buffer and incubated with appropriate
antibodies for 30 min at 4 ◦C—LRP-1 (CD91-PE, Clone REA709, 130-111-412, Miltenyi
Biotec, Bergisch Gladbach, Germany). After washing in PBS, cells were analyzed with
a FACSCanto II flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
4.5. Analysis of EphA4 mRNA Levels by qPCR
Total RNA was extracted from TIMP-3/HEK or HEK cells by using Qiagen RNeasy
mini kit (Qiagen, Hilden, Germany) and reversely transcribed (1 µg) with Quantitect
Reverse Transcription kit (Qiagen), following the manufacturer’s instructions. RT-qPCR
was performed by using corresponding primers and SYBR Select Master Mix (Thermo
Scientific) on a 7500 fast Real-Time PCR Detection System (Applied Biosystem, Part of
Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions.
The forward and reverse primers used for target genes were purchased from Bio-Rad
(Unique Assay ID: qHsaCID0017961; Bio-Rad, Hercules, CA, USA). Relative fold change
was calculated by first normalization with the reference gene GAPDH (Unique Assay ID:
qHsaCED0038674, Bio-Rad, Hercules, CA, USA) and then against the level in control cells
and presented as 2−∆∆CT.
4.6. Exogenous TIMP-3 Induces Accumulation of EphA4
TIMP-3/HEK or HEK controls were grown until confluence in 10 cm dishes prior to
being incubated in serum-free medium for 48 h. Conditioned media were harvested and
accumulation of FLAG-tagged TIMP-3 was confirmed using Western blotting (anti-FLAG
M2; Sigma, Aldrich, St. Louis, MO, USA). HEK 293 cells were incubated for 24 h with
conditioned media containing or not containing TIMP-3, then cells were collected in STET
lysis buffer and levels of EphA4 analyzed using Western blotting.
4.7. Dose-Dependent Effects of Hygromycin B on EphA4 Levels
TIMP-3/HEK cells were maintained for 2 weeks in different concentrations of hy-
gromycin B (0–800 µg/mL). Then, TIMP-3/HEKs were grown until confluence in 6-well
plates, incubated for 24 h in serum-free medium, and harvested in STET lysis buffer. Levels
of EphA4 in TIMP-3/HEKs were analyzed using Western blotting and compared to those
in HEK controls cells. Similarly, HEK 293 cells were transfected with the empty pCEP4
expression vector and hygromycin B resistant cells were selected by adding 400 µg/mL
hygromycin B to the growth medium. Hygromycin-resistant HEK 293 cells were seeded
in 6-well plates, grown to confluence with or without 400 µg/mL hygromycin B, and
then lysed with a STET buffer. Levels of EphA4 were evaluated using Western blotting.
Viability of cells grown with different concentrations of hygromycin B was evaluated by
CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI, USA), following
the manufacturer’s instructions.
Supplementary Materials: Supplementary materials can be found at https://www.mdpi.com/1422
-0067/22/5/2392/s1.
Author Contributions: A.P.C., V.M.P., D.D., and E.M. performed experiments; M.C. supervised
experiments and analyzed data; S.B. analyzed the proteomic data; S.A.M. designed and supervised
proteomic experiments; S.F.L. analyzed data and wrote the manuscript; S.D.S. conceived the study,
Int. J. Mol. Sci. 2021, 22, 2392 17 of 19
designed experiments, analyzed data, and wrote the manuscript. All authors have read and agreed
to the published version of the manuscript.
Funding: This research was partially supported by Fondazione con il Sud under the Programme
“Brains to South 2018”—Project “i-Rhom2: a new therapeutic target in osteoarthritis” (Grant Agree-
ment No. 2018—PDR—00799), by the Deutsche Forschungsgemeinschaft (DFG, German Research
Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for
Systems Neurology (EXC 2145 SyNergy—ID 390857198) and by Patto per il Sud Regione Siciliana –
Grant “CheMISt” (CUP G77B17000110001).
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are available in Supplementary
Materials.
Acknowledgments: We wish to thank the Structural Biology and Biophysics Laboratory at Fon-
dazione Ri.MED for technical support.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
TIMPs Tissue inhibitor of metalloproteases
ADAMs A disintegrin and metalloproteinases
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